ILA Insider Trading

Insider Ownership Percentage: 73.21%
Insider Buying (Last 12 Months): A$11,523.21
Insider Selling (Last 12 Months): A$0.00

Island Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Island Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Island Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 11/22/2021 11:10 AM ET

This chart shows the closing price history over time for ILA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
The Ultimate Passive Income Play
The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas. 

Find Out What It Is Right Here.

Island Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/4/2023Albert HansenInsiderExpiry23,030A$0.07A$1,612.10
8/3/2022David FosterInsiderBuy31,303A$0.20A$6,323.21
6/21/2022David FosterInsiderBuy40,000A$0.13A$5,200.00
11/18/2021David BrookesInsiderIssued100,000A$0.25A$25,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Island Pharmaceuticals (ASX:ILA)

4.32% of Island Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.
Read More on Island Pharmaceuticals

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A



Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Island Pharmaceuticals?

Island Pharmaceuticals' top insider investors include:
  1. Albert Hansen (Insider)
  2. David Brookes (Insider)
  3. David Foster (Insider)
Learn More about top insider investors at Island Pharmaceuticals.